For healthcare professionals

Know today whether your patient with diabetes will lose kidney function over the next 4 years.

INNOVATIO-ND2 is a predictive test based on protein biomarkers. eGFR and ACR tell you how the kidney is today; INNOVATIO-ND2 tells you where it is heading and how fast, from a single blood sample.

CPT 0385U · Covered by Traditional Medicare, MCS (Advantage and commercial) and MMM (Advantage and Vital)

Kidney drawn as a network of molecules, highlighting the biomarkers ApoA4, CD5L and IGFBP3

One test, three answers

Validated as a predictive test in more than 4,000 patients, including the CANVAS study population.

1 · Diagnosis

Is diabetic kidney disease already present?

A result above 30% indicates kidney disease is present, even when ACR and eGFR look normal.

2 · 4-year prognosis

Will eGFR fall by 30% or more?

Classifies the risk of an eGFR decline of 30% or more over the next 4 years as low, medium or high.

3 · Speed

Fast or slow progression?

When kidney damage is present, it separates slow, medium and fast progressors without years of serial eGFR.

What each test tells you

What each test tells you
TestCurrent kidney functionFuture kidney functionRate of decline
INNOVATIO-ND2YesYesYes
Urine albumin-to-creatinine ratio (ACR)YesNoNo
Estimated glomerular filtration rate (eGFR)YesNoNo

ACR and eGFR only detect diabetic kidney disease once damage has occurred, and they are not always conclusive. INNOVATIO-ND2 identifies the risk earlier, so you can tailor the plan and track the response.

Each risk level comes with a plan

The report does more than classify: it tells you what to adjust and when to retest.

Low risk
Does not mean "no risk".Standard diabetes care.Repeat in 12 months
Medium risk
Kidney-protective medications; avoid nephrotoxic drugs (NSAIDs).Tight control of blood pressure, lipids and HbA1c; smoking, alcohol and weight.Repeat in 6 months
High risk
The medium-risk plan, with greater intensity and urgency.Candidate for kidney-protective therapy (ACEi/ARB, SGLT2i, GLP-1 RA, finerenone).Repeat in 3–4 months
Reading example. Diagnostic score 40%: above 30%, kidney damage is present. Prognostic risk 16%: moderate risk.
When kidney damage is present, prognosis reads as speed: low = slow, medium = faster, high = rapid decline.

Clinical interpretation guide

A sample report explained: how to read diagnosis and prognosis, and what to do at each risk level (in Spanish).

Download PDF

Which patients are candidates?

Preserved kidney function

eGFR above 60 and/or no microalbuminuria

They look "healthy", but their prognosis is uncertain. Knowing future risk lets you adjust the plan before damage appears.

Known kidney disease

Stages 1 to 4

You know the stage; now learn whether it is progressing slowly, moderately or fast, and act with the right urgency.

How to order

  1. 1Patient with type 2 diabetes, fasting.
  2. 2Physician order with ICD-10 code E11.22 or E11.8 and CPT 0385U, signed with license and NPI. Download the order form (in Spanish)
  3. 3Blood draw at one of 56 experienced laboratories in 32 towns, or at any Laboratorios Borinquen branch. See laboratories by town
  4. 4Processing at Immuno Reference Lab, in a monthly run.
Request printed order forms on WhatsApp

The evidence

PromarkerD algorithm: three blood biomarkers (ApoA4, CD5L and IGFBP3) combined with age, HDL and eGFR.

Validated in the CANVAS study: Peters KE et al., Journal of Clinical Medicine, 2020. The ELISA assay is clinically equivalent to the original mass-spectrometry platform.

With kidney-protective therapies available (ACEi, ARB, SGLT2i, GLP-1 RA, finerenone), knowing the risk lets you act and measure the response on follow-up tests.

See all studies →

Thinking of a patient with diabetes and a "normal" eGFR who worries you?

In 10 minutes I'll show you how to read the result and how it fits your practice.

Luben Ron · CEO and Co-Founder · luben.ron@omicssolutions.com